Gilead Sciences, Inc.

Q2 2025 13F Holdings Report, Stock Holdings

Signature - Title
Andrew D. Dickinson - Executive Vice President and Chief Financial Officer
Location
Foster City, CA
Holdings as of
June 30, 2025
Value $
$1.28B
Num holdings
14
Date filed
8/14/2025, 10:58 AM
Form type
13F-HR
Description
All US holdings of this investor are reported in this report. Top holdings included GLPG, ACLX, RCUS, ASMB, and TNGX.
Previous filing
Q1 2025 - May 13, 2025
SEC
View on sec.gov
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2025 Q2 compared to 2025 Q1 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Andrew D. Dickinson Executive Vice President and Chief Financial Officer Foster City, California 8/14/2025

Other Included Managers (1):

Num Name Location File Number
1 Gilead Therapeutics A1 Unlimited Co Co Cork, Ireland 028-25083